RRAM
BMRN icon

River Road Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

River Road Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.1M Sell
542,990
-374,622
-41% -$20.5M 0.35% 85
2026
Q1 		$51.8M Buy
917,612
+11,246
+1% +$656K 0.59% 60
2025
Q4 		$53.9M Buy
+906,366
New +$49.3M 0.59% 64

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

River Road Asset Management's BMRN Position: Q2 2026 in Review

River Road Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 41% in Q2 2026, selling an estimated $20.5M and leaving 542,990 shares worth $31.1M. The position accounts for 0.35% of the portfolio, ranked #85.

River Road Asset Management first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $53.9M in Q4 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • River Road Asset Management held 542,990 shares of BioMarin Pharmaceuticals worth $31.1M as of Q2 2026.
  • River Road Asset Management sold 374,622 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $20.5M.
  • BioMarin Pharmaceuticals made up 0.35% of River Road Asset Management's portfolio in Q2 2026, its #85 holding.
  • River Road Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • River Road Asset Management's BioMarin Pharmaceuticals position peaked at $53.9M in Q4 2025.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on River Road Asset Management's 13F filing for Q2 2026, filed 17 Jul 2026.